Progress in clinical immunotherapy for tumors.
Immunotherapy of human tumors is a promising new modality that remains highly investigational and poses unforeseen risks. It should preferably be conducted in patients brought into remission by conventional antitumor therapy and against the background of a complex, reliable monitoring system capable of quantitatively measuring the patient's antitumor immune reactions.
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D001500:BCG Vaccine / Q000627:therapeutic use; D004195:Disease Models, Animal; D000882:Haplorhini; D006564:Herpesviridae / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012107:Research Design; D013950:Thymus Gland / Q000637:transplantation; D014765:Viral Vaccines / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D014765:Viral Vaccines